Answers are grounded in this paper and cite their sources.
Chronic lymphocytic leukaemia (CLL) is defined not only by disease biology but also by time. Its natural history reflects the pace of clonal evolution, the changing reserve of host immunity, the ordered use of therapeutic classes and the time patients seek to preserve outside illness and treatment. The expansion of highly active targeted therapies has shifted the clinical challenge from selecting an effective regimen to managing a longitudinal therapeutic trajectory. We propose a four-clock framework for CLL care. The clonal clock captures evolutionary tempo and biological urgency; the immune clock captures host immune reserve and recoverability; the therapeutic clock captures treatment exposure, resistance and preservation of future options; and the human clock captures patient-valued time, treatment burden and tolerance for uncertainty. Discordance among these clocks may be more informative than any single baseline risk factor. Therapeutic stewardship aims to align treatment intensity, duration, sequencing, monitoring and supportive care with the clock driving risk at each transition while minimising avoidable harm to the others. This framework is not a validated score or a substitute for guidelines, but an integrative clinical reasoning model that makes discordance among established domains explicit and supports their repeated reassessment at clinically meaningful transitions. Its proposed educational and clinical utility requires prospective evaluation.
No takes yet. Share an insight, caveat, or question.
Morabito et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: